Gene Tek psychotherapy Tecentriq and chemotherapy in combination with the treatment of small cell lung cancer, their survival period reached the main clinical endpoint

recent days, Roche Group's Genentechcompanysaid that the company's immunotherapy Tecentriq and chemotherapy, in the treatment of small cell lung cancer, total survival (OS) and non-progressive survival (PFS) in the treatment of small cell lung cancer have reached the main clinical endit is also the first immune therapy combination to demonstrate an improved combination of OS and PFS in the treatment of small cell lung cancertecentriqas the first approved anti-PD-L1 therapy, tecentriq, which is introduced by GeneTec, effectively binds to the PD-L1 expressed on the surface of tumor cells and tumor-immersed immune cells, inhibiting their binding to PD-1 and B7.1 receptors, allowing them to reactivate T-cells and allow them to attack tumorssince thewas first approved, Tecentriq's individual and combination therapies have yielded good results in a wide range of cancersstudies
the therapeutic potential of tecentriq in combination with calyse and etoposide in small cell lung cancer was demonstrated in a clinicaltrialcalled IMpower133 3, multicenter, double-blind, randomized placebo-controlledthe study recruited 403 patients and were randomly divided into two groups with a 1:1 ratio, one receiving tecentriq combination therapy and the other receiving only a combination of placebo and calycoside treatmentstudies have shown that Tecentriq's combination therapy has reached the primary clinical endpoint of the common OS and PFSSpecific data will be published at future medicalmeetings